NYSE Listed Company Manual

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

Retrieved on: 
Monday, November 13, 2023

SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2, 2023 (the “Shareholders”) of the importance of a vote FOR the various proposals detailed below at the upcoming special meeting of Shareholders to be held on November 28, 2023 (the “Special Meeting”) as a virtual meeting only.

Key Points: 
  • SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2, 2023 (the “Shareholders”) of the importance of a vote FOR the various proposals detailed below at the upcoming special meeting of Shareholders to be held on November 28, 2023 (the “Special Meeting”) as a virtual meeting only.
  • IntelGenx wishes to inform that the Company has been advised that the Autorité des marchés financiers (“AMF”) considers the Financing Transactions are subject to the minority vote prescribed by Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions.
  • As set out in the Proxy Statement, the board of directors of IntelGenx believes the Financing Transactions are in the best interest of the Company and unanimously recommends that the Shareholders vote “FOR” all matters put to a vote at the Special Meeting.
  • IntelGenx strongly encourages all Shareholders who would like to attend, participate and/or vote virtually online to carefully follow the procedures outlined in the Proxy Statement.

Finance of America Receives Continued Listing Standard Notice from the NYSE

Retrieved on: 
Friday, December 15, 2023

The New York Stock Exchange (the “NYSE”) requires that companies with shares listed on the NYSE comply with the NYSE’s continued listed standards.

Key Points: 
  • The New York Stock Exchange (the “NYSE”) requires that companies with shares listed on the NYSE comply with the NYSE’s continued listed standards.
  • The Notice has no immediate effect on the listing of the Class A Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements.
  • Finance of America plans to notify the NYSE within ten business days of its receipt of the Notice that it intends to bring the Company into compliance with this listing standard within the six month cure period.
  • Finance of America intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE’s continued listing standards.

Catalent Regains Compliance with NYSE Continued Listing Standards

Retrieved on: 
Friday, December 15, 2023

Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE continued listing standards.

Key Points: 
  • Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE continued listing standards.
  • Following the filing by the Company on December 8, 2023 of its Annual Report on Form 10-K for the year ended June 30, 2023 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the NYSE’s Notice cured Catalent of the previously disclosed non-compliance with exchange listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual and removed the Company from the noncompliant issuers list on the NYSE website at www.nyse.com .

Regis Announces Intent to Appeal NYSE Determination to Commence Proceedings to Delist Regis’ Common Stock

Retrieved on: 
Friday, December 15, 2023

Regis Corporation (NYSE: RGS), a leader in the haircare industry, will be appealing the NYSE’s decision to commence proceedings to delist Regis’ common stock from the New York Stock Exchange (“NYSE”) within the required timing.

Key Points: 
  • Regis Corporation (NYSE: RGS), a leader in the haircare industry, will be appealing the NYSE’s decision to commence proceedings to delist Regis’ common stock from the New York Stock Exchange (“NYSE”) within the required timing.
  • Regis looks forward to presenting its plan of compliance at the hearing, and in the interim, will continue to evaluate all available listing options.
  • While Regis intends to appeal, NYSE reserves the right under subsequent committee review to determine that trading in Regis common stock should be suspended.
  • During this time, Regis common stock has not been suspended from trading and is expected to continue to be listed and traded on the NYSE while any appeal remains pending.

NYSE Announces Intent to Commence Delisting Proceedings for Regis Corporation Common Stock; Opportunity to Appeal

Retrieved on: 
Thursday, December 14, 2023

Regis Corporation (NYSE: RGS), a leader in the haircare industry, has been informed that NYSE Regulation has determined to commence proceedings to delist Regis’ common stock from the New York Stock Exchange (“NYSE”).

Key Points: 
  • Regis Corporation (NYSE: RGS), a leader in the haircare industry, has been informed that NYSE Regulation has determined to commence proceedings to delist Regis’ common stock from the New York Stock Exchange (“NYSE”).
  • Regis common stock has not been suspended from trading and is expected to continue to be listed and traded on the NYSE while the company considers whether to request a review of NYSE’s determination to commence delisting proceedings and, if such a review is requested, while any such review remains pending.
  • NYSE Regulation has determined that Regis was unable to demonstrate that it had regained compliance with the applicable listing standard by the expiration of the maximum plan period.
  • Regis has a right to a review of the NYSE’s determination by a Committee of the Board of Directors of the NYSE (the “Committee”).

NYSE to Commence Delisting Proceedings Against Regis Corporation (RGS)

Retrieved on: 
Wednesday, December 13, 2023

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Regis Corporation (the “Company”) — ticker symbol RGS — from the NYSE.

Key Points: 
  • The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Regis Corporation (the “Company”) — ticker symbol RGS — from the NYSE.
  • NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 802.02 of the Listed Company Manual as the Company was unable to demonstrate that it had regained compliance with the applicable listing standard by the expiration of the maximum plan period.
  • The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange (the “Committee”).
  • After the suspension announcement, the NYSE would then apply to the Securities and Exchange Commission to delist the common stock.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Monday, December 11, 2023

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and restricted stock units to acquire a total of 9,800 shares of the Company’s common stock.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and restricted stock units to acquire a total of 9,800 shares of the Company’s common stock.
  • The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of KORE Group Holdings, Inc. (KORE.WS)

Retrieved on: 
Wednesday, December 6, 2023

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of KORE Group Holdings, Inc. (the “Company”), each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share (the “Warrants”) — ticker symbol KORE.WS — from the NYSE.

Key Points: 
  • The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of KORE Group Holdings, Inc. (the “Company”), each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share (the “Warrants”) — ticker symbol KORE.WS — from the NYSE.
  • Trading in the Company’s Warrants will be suspended immediately.
  • Trading in the Company’s common stock — ticker symbol KORE — will continue on the NYSE.
  • NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of UpHealth, Inc. (UPH.WS)

Retrieved on: 
Tuesday, November 28, 2023

Trading in the Company’s Warrants will be suspended immediately.

Key Points: 
  • Trading in the Company’s Warrants will be suspended immediately.
  • Trading in the Company’s common stock — ticker symbol UPH —will continue on the NYSE.
  • NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.
  • The NYSE will apply to the Securities and Exchange Commission to delist the Warrants upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Getaround, Inc. (GETR WS)

Retrieved on: 
Tuesday, November 28, 2023

Trading in the Company’s Warrants will be suspended immediately.

Key Points: 
  • Trading in the Company’s Warrants will be suspended immediately.
  • Trading in the Company’s common stock — ticker symbol GETR —will continue on the NYSE.
  • NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.
  • The NYSE will apply to the Securities and Exchange Commission to delist the Warrants upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.